{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-091958","form_type":"8-K","ticker":"TRAW","cik":"0001130598","company_name":"Traws Pharma, Inc.","filed_at":"2023-08-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.208363+00:00","generated_at":"2026-06-11T09:12:27.135018+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Onconova stockholders elect eight directors, approve say-on-pay and auditor ratification at 2023 annual meeting","bullets":["Elected all eight director nominees with majority 'For' votes; broker non-votes 3,588,614 each.","Advisory say-on-pay approved: 4,959,016 For, 1,066,808 Against, 900,578 Abstain.","Ratification of Ernst & Young as auditor approved: 9,271,526 For, 368,397 Against, 875,093 Abstain.","Quorum achieved with 10,515,016 shares represented after prior adjournment on July 21, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-091958","json":"https://secwatch.observer/filing/0001104659-23-091958.json","markdown":"https://secwatch.observer/filing/0001104659-23-091958.md","text":"https://secwatch.observer/filing/0001104659-23-091958.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1130598/000110465923091958/0001104659-23-091958-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1130598/000110465923091958/tm2323845d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T09:12:27.135018+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"40de8b531317723a8c754356ecb56e4f7c33735f","claim":"Traws Pharma, Inc. shareholders approved To elect eight directors, each to hold office until the 2024 Annual Meeting of Stockholders and until his or her successor is elected and qualified. at the 2023-08-10 meeting.","evidence_excerpt":"Proposal 1. To elect eight directors, each to hold office until the 2024 Annual Meeting of Stockholders and until his or her successor is elected and qualified. Each nominee for director was elected by a vote of the stockholders as follows: Nominee For Withheld Broker Non-Votes James J. Marino 5,541,973 1,384,429 3,588,614 Steven M. Fruchtman 5,555,005 1,371,397 3,588,614 Peter Atadja 5,670,083 1,256,319 3,588,614 Trafford Clarke 5,541,659 1,384,743 3,588,614 Jerome E. Groopman 5,537,395 1,389,007 3,588,614 Viren Mehta 5,570,427 1,355,975 3,588,614 M. Teresa Shoemaker 5,592,043 1,334,359 3,588,614 Jack E. Stover 5,559,133 1,367,269 3,588,614","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1130598/000110465923091958/0001104659-23-091958-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-08-10"}],"fact_type":"shareholder_vote"},{"claim_id":"40ee868170b40a997b2451fcc662c1f0b376ab23","claim":"Traws Pharma, Inc. shareholders approved To approve, on an advisory basis, the compensation of our named executive officers. at the 2023-08-10 meeting.","evidence_excerpt":"Proposal 2. To approve, on an advisory basis, the compensation of our named executive officers. The proposal was approved by a vote of the stockholders as follows: For Against Abstain Broker Non-Votes 4,959,016 1,066,808 900,578 3,588,614","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1130598/000110465923091958/0001104659-23-091958-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-08-10"}],"fact_type":"shareholder_vote"},{"claim_id":"afd5813781947e4421c94d19b4fb319ce1a2005c","claim":"Traws Pharma, Inc. shareholders approved To consider and vote upon the ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023. at the 2023-08-10 meeting.","evidence_excerpt":"Proposal 3. To consider and vote upon the ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023. The proposal was approved by a vote of the stockholders as follows: For Against Abstain Broker Non-Votes 9,271,526 368,397 875,093 -","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1130598/000110465923091958/0001104659-23-091958-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-08-10"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}